Core Viewpoint - The company has approved a share repurchase plan with a total funding amount between 300 million RMB and 600 million RMB, with a maximum repurchase price of 53.5 RMB per share [1] Group 1: Share Repurchase Plan - The company convened the 27th meeting of the 6th Board of Directors on October 13, 2025, to review and approve the share repurchase plan [1] - The total amount spent on share repurchase as of October 21, 2025, is 204,352,396.47 RMB, with a total of 5,076,901 shares repurchased, accounting for 1.09% of the company's total share capital [1] - The highest transaction price during the repurchase was 40.883 RMB per share, while the lowest was 39.83 RMB per share [1] Group 2: Compliance with Regulations - The company has adhered to the relevant regulations regarding the timing, quantity, and price of the share repurchase, as outlined in the Shenzhen Stock Exchange's self-regulatory guidelines [2] - The company did not repurchase shares during periods that could significantly impact the stock price or during other restricted periods as defined by regulatory authorities [2][3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required [3]

Core Viewpoint - Tianjin Jiuan Medical Electronics Co., Ltd. has initiated its share repurchase plan, marking a significant step in its financial strategy [1][2]. Group 1: Share Repurchase Details - On October 15, 2025, the company completed its first share repurchase, acquiring 946,400 shares, which represents 0.20% of its total share capital, for a total transaction amount of 37.86 million yuan [1][2]. - The board approved a share repurchase plan on October 13, 2025, with a total funding of no less than 300 million yuan and no more than 600 million yuan, and a maximum repurchase price of 53.5 yuan per share [2]. Group 2: Compliance and Future Disclosures - The company will disclose the share repurchase details on the trading day following the repurchase, in accordance with regulatory guidelines [3]. - Jiuan Medical has committed to not conducting repurchases during periods that could affect stock prices due to significant events, adhering to regulations set by the China Securities Regulatory Commission and Shenzhen Stock Exchange [3].

Group 1 - The core viewpoint of the news is that Jiuan Medical has experienced fluctuations in its stock performance and financing activities, indicating a high level of trading activity and investor interest [1][2]. - On August 29, Jiuan Medical's stock price decreased by 0.20%, with a trading volume of 351 million yuan. The net financing buy was negative at -29.59 million yuan, indicating more selling than buying in the financing market [1]. - As of August 29, the total balance of margin trading for Jiuan Medical was 1.266 billion yuan, with a financing balance of 1.259 billion yuan, representing 6.72% of its market capitalization, which is above the 90th percentile of the past year [1]. Group 2 - As of August 10, the number of Jiuan Medical's shareholders increased by 2.24% to 73,000, while the average number of circulating shares per person decreased by 2.19% to 6,491 shares [2]. - For the first half of 2025, Jiuan Medical reported a revenue of 765 million yuan, a year-on-year decrease of 43.35%, while the net profit attributable to shareholders increased by 52.91% to 920 million yuan [2]. - The company has distributed a total of 1.794 billion yuan in dividends since its A-share listing, with 1.39 billion yuan distributed in the last three years [2].